Hyoscine Butylbromide
Brand names: Buscopan
Hyoscine butylbromide is an antimuscarinic antispasmodic used for abdominal or genitourinary smooth-muscle spasm (e.g. in irritable bowel syndrome or colic) and for secretions in palliative care.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It blocks muscarinic receptors on smooth muscle, relaxing spasm; it crosses the blood-brain barrier poorly, so central effects are limited.
Prescribing in practice
- Given intravenously it can cause serious tachycardia and hypotension — use caution and have monitoring in patients with cardiac disease (MHRA).
- Antimuscarinic cautions apply — avoid in narrow-angle glaucoma, significant bladder-outflow obstruction and gastrointestinal obstruction.
- Oral absorption is low, so the oral form mainly acts locally in the gut.
Monitoring
For intravenous use, monitor heart rate and blood pressure, especially in cardiac disease.
Counselling the patient
- It can cause dry mouth and blurred vision.
- Report difficulty passing urine or eye pain.
Evidence & guidelines
An antispasmodic for smooth-muscle colic and for secretions in palliative care, with an MHRA caution about intravenous use in cardiac disease.
Reference: NICE CG61 IBS; SPC Buscopan; NICE Palliative Care Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021